Climb Biotherapeutics, Inc. (CLYM)
Market Closed
30 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
12. 08
-0.03
-0.2477%
$
870.03M Market Cap
- P/E Ratio
- Div Yield
1.8M Volume
0 Eps
$ 12.11
Previous Close 
Want to track CLYM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Climb Biotherapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 59,090 | $236,360 | $722,079.8 | $485,719.8 | 205.5% |
| KJ Ken Joseph Braidwel LLP | 1.53M | $10.48M | $18.91M | $8.43M | 80.44% |
 George Song Superstring Capital Management LP | 199,209 | $1.36M | $2.43M | $1.07M | 78.39% |
 Drew Phillips Fortitude Family Office LLC | 92 | $630 | $1,168.4 | $538.4 | 85.46% |
 Christopher C. Powers Farther Finance Advisors, LLC | 821 | $10,706 | $10,032.62 | -$673.38 | -6.29% |
 Zachary Canonico DIADEMA PARTNERS LP | 286,126 | $1.96M | $3.69M | $1.73M | 88.15% |
 AMY TEH Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 24,590 | $168,442 | $318,317.55 | $149,875.55 | 88.98% |
 Scott Schroeder Longaeva Partners LP | 217,768 | $1.49M | $2.8M | $1.31M | 87.52% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 72,325 | $448,824.63 | $928,291.37 | $479,466.74 | 106.83% |
